January 7, 2019

SALT LAKE CITY — Recursion, a clinical-stage biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited (Takeda) to evaluate and identify novel preclinical candidates for rare diseases. In less than 18 months, this collaboration has resulted in the evaluation of Takeda preclinical and clinical molecules in over 60 unique indications, with new therapeutic candidates identified for over half a dozen diseases. Takeda has exercised its option for drug candidates in two rare diseases from these early results. Takeda and Recursion have also extended the partnership to enable additional discoveries to be made and evaluated by both teams. Financial details were not disclosed.

“We’re thrilled with the momentum this partnership has established in such a short amount of time, as we work towards our shared vision for what artificial intelligence in drug discovery can achieve,” said Chris Gibson, co-founder and CEO of Recursion. “Takeda is undoubtedly at the forefront of adopting this technological convergence, and it has been great to work with their team and to see their dedication to rigorous science and rapidly advancing programs for a range of unmet needs.”